[Recent progress of biological agents in collagen-vasucular diseases].
Takeuchi
Tsutomu
T
Division of Rheumatology, Saitama Medical Center, Saitama Medical University. tsutake@saitama-med.ac.jp
D000068879:Adalimumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000627:therapeutic use; D003095:Collagen Diseases / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D008565:Membrane Proteins / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D001688:Biological Products; D015815:Cell Adhesion Molecules; D016207:Cytokines; C106607:FCGBP protein, human; D007074:Immunoglobulin G; D008565:Membrane Proteins; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept